12,476 press releases in English indexed under finance.
Built on Equimundo: Center for Masculinity & Social Justice's research into boyhood and masculinity, the game aims to raise awareness among young people about the attitudes and behaviours that contribute towards violence against women and girls. NEW YORK, Oct. 7, 2026 -- The...
The Beyond Now Agentic Revenue & Ecosystem Orchestration Platform brings revenue, multi-party ecosystems and agentic AI together across the entire revenue lifecycle — helping CSPs and technology providers turn AI disruption into growth. DUBLIN, Oct. 7, 2026 -- Beyond Now...
STOCKHOLM, Oct. 7, 2026 -- In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April 2024, the number of shares that each warrant entitles the holder to subscribe for and the subscription...
Syncron launches Service Contract Performance to help OEMs predict costs, optimize pricing and protect margins on service contracts and warranties.
HOUSTON, Oct. 07, 2026 -- VAALCO Energy, Inc. (NYSE: EGY, LSE: EGY) (“Vaalco” or the “Company”) announced successful completion of the offshore Gabon Phase 3 drilling program, including encouraging initial well results on the ETSEM-3H well and demobilization of the rig from the SE Etame platform. Additionally, the Company provided updates on the recently commenced Baobab drilling program offshore Côte d’Ivoire.
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 7 OCTOBER 2026 at 9.00 EEST
New York, New York--(October 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of The Simply Good Foods Company (NASDAQ: SMPL) between October 24, 2024 and April 8, 2026, inclusive (the "Class Period"), of the important October 13, 2026 lead plaintiff deadline.SO WHAT: If you purchased Simply Good Foods common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
New York, New York--(October 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
New York, New York--(October 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lincoln Educational Services Corporation (NASDAQ: LINC) between May 11, 2026 and August 9, 2026, inclusive (the "Class Period"), of the important November 10, 2026 lead plaintiff deadline.SO WHAT: If you purchased Lincoln Educational Services securities during the Class Period you may be entitled to compensation without payment of any out of pocket...
New York, New York--(October 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Hims securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
New York, New York--(October 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds open market purchasers of common stock of Honeywell Aerospace Inc. (NASDAQ: HONA) between June 29, 2026 and September 1, 2026, both dates inclusive (the "Class Period"), of the important November 23, 2026 lead plaintiff deadline.SO WHAT: If you purchased Honeywell Aerospace common stock on the open market during the Class Period you may be entitled to compensation without...
SAN CARLOS, Calif., Oct. 06, 2026 -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants to purchase 400,000 shares of common stock and $500 million aggregate principal amount of 1.50% convertible senior notes due 2032 (the “notes”). The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The shares of common stock, pre-funded warrants and notes to be sold in the offerings are being offered by Vaxcyte. Vaxcyte has granted the underwriters of the common stock and pre-funded warrant offering a 30-day option to purchase up to an additional 1,171,875 shares of its common stock at the public offering price per share, and has granted the underwriters of the note offering a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes at the public offering price, solely to cover over-allotments, in each case less underwriting discounts and commissions.